Liou Yi-Sheng, Chen Hung-Yi, Tien Lyun, Gu Yi-Sian, Jong Gwo-Ping
From the Department of Family Medicine and Geriatrics, Taichung Veteran General Hospital, and School of Public Health, National Defense Medical Center, Taipei, Taiwan, ROC (Y-SL); Department of Pharmacy, China Medical University and China Medical University Beigang Hospital, Taichung, Taiwan, ROC (H-YC); and Department of Pharmacy, China Medical University Hospital and China Medical University Beigang Hospital, Taichung and Beigang Township, Yunlin County, Taiwan, ROC (H-YC, Y-SG); Central Region Branch, Bureau of National Health Insurance, Taichung, Taiwan, ROC (L-T); and Division of Internal Cardiology, Chung Shan Medical University Hospital and Chung Shan Medical University, and Basic Science, Central Taiwan University of Science and Technology, Taichung, Taiwan, ROC (G-PJ).
Medicine (Baltimore). 2015 Sep;94(36):e1495. doi: 10.1097/MD.0000000000001495.
Antihypertensives have been linked to new-onset diabetes (NOD) and different classes of antihypertensives may alter the risk for the development of NOD; however, the effect of different antihypertensives on the development of NOD in women with hypertension and coronary artery disease (CAD) has not been well studied. The purpose of this study is to investigate the association between usage of different antihypertensive drugs and the development of NOD in female patients with hypertension and CAD.Data in this retrospective cohort study were obtained from claim forms submitted to the Taiwan Bureau of National Health Insurance in central Taiwan during the period 2006-2011. We estimated the odds ratios (OR) to approximate the relative risk of NOD development associated with antihypertensive drug use.Of the 20,108 female patients with CAD at baseline, 2288 patients developed NOD during the 6-year follow-up. Subjects treated with angiotensin-converting enzyme (ACE) inhibitors (OR, 0.92; 95% confidence interval [CI], 0.84-1.00), angiotensin receptor blockers (OR, 0.92; 95% CI, 0.82-0.99), and alpha-blockers (OR, 0.88; 95% CI, 0.79-0.98) in the adjusted analyses had greater reductions of the risk than among nonusers. Patients who took diuretics (OR, 1.10; 95% CI, 1.01-1.20), beta-blockers (OR, 1.12; 95% CI, 1.04-1.21), and calcium channel blockers (OR, 1.10; 95% CI, 1.02-1.18) were at high risk of developing NOD than nonusers. Vasodilators were not associated with risk of NOD.We conclude that women with hypertension who take ACE inhibitors, angiotensin receptor blockers, and alpha-blockers are at lower risk of NOD and that use of diuretics, beta-blockers, and calcium channel blockers was associated with a significantly increased risk of developing NOD during the 6-year follow-up.
抗高血压药物与新发糖尿病(NOD)有关,不同类别的抗高血压药物可能会改变患NOD的风险;然而,不同抗高血压药物对患有高血压和冠状动脉疾病(CAD)的女性发生NOD的影响尚未得到充分研究。本研究的目的是调查不同抗高血压药物的使用与患有高血压和CAD的女性患者发生NOD之间的关联。这项回顾性队列研究的数据来自2006年至2011年期间提交给台湾中部地区国民健康保险局的理赔申请表。我们估计了比值比(OR),以近似与使用抗高血压药物相关的NOD发生的相对风险。在基线时的20108名患有CAD的女性患者中,有2288名患者在6年随访期间发生了NOD。在调整分析中,接受血管紧张素转换酶(ACE)抑制剂治疗的受试者(OR,0.92;95%置信区间[CI],0.84 - 1.00)、血管紧张素受体阻滞剂(OR,0.92;95% CI,0.82 - 0.99)和α受体阻滞剂(OR,0.88;95% CI,0.79 - 0.98)与未使用者相比,风险降低幅度更大。服用利尿剂(OR,1.10;95% CI,1.01 - 1.20)、β受体阻滞剂(OR,1.12;95% CI,1.04 - 1.21)和钙通道阻滞剂(OR,1.10;95% CI,1.02 - 1.18)的患者比未使用者发生NOD的风险更高。血管扩张剂与NOD风险无关。我们得出结论,服用ACE抑制剂、血管紧张素受体阻滞剂和α受体阻滞剂的高血压女性患NOD的风险较低,而在6年随访期间,使用利尿剂、β受体阻滞剂和钙通道阻滞剂与发生NOD的风险显著增加有关。